Ebos GroupASX:EBO +0.30%77 Net Margin % is 1.84% as of Dec. 2025, which is 5% below its 10-year median of 1.93. GuruFocus rates ASX:EBO with a GF Score™ of 77/100 and a GF Value™ of A$31.49 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 119 Medical Distribution companies, Ebos Group ranks better than 52.94% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Ebos Group's Net Income for the
six
months ended in Dec. 2025 was A$126 Mil. Ebos Group's Revenue for the
six
months ended in Dec. 2025 was A$6,828 Mil. Therefore, Ebos Group's net margin for the quarter that ended in Dec. 2025 was 1.84%.
The historical rank and industry rank for Ebos Group's Net Margin % or its related term are showing as below:
ASX:EBO'
s Net Margin % Range Over the Past 10 Years
Min: 1.74 Med: 1.93 Max: 2.07
Current: 1.76
ASX:EBO's Net Margin % is ranked better than 52.94% of 119
companies
in the Medical Distribution industry
Industry Median: 1.53
vs ASX:EBO: 1.76
Ebos Group (ASX:EBO) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Ebos Group Net Margin % Related Terms
Ebos Group Net Margin % Historical Data
* Premium members only.
The historical data trend for Ebos Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ebos Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Net Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where Ebos Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group (ASX:EBO) has a Net Margin % of 1.84% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Ebos Group and its competitors. This is near median its historical median of 1.93. Over the past decade, Ebos Group's Net Margin % has ranged from 1.74 to 2.07. According to the industry distribution chart, Ebos Group ranks #56 out of 119 companies in the Medical Distribution industry, placing it in the top 47.1%.
Is Ebos Group's Net Margin % too high?
Ebos Group's current Net Margin % of 1.84% is near median its 10-year median of 1.93. Over the past 10 years, this metric has ranged from a low of 1.74 to a high of 2.07. The Medical Distribution industry median Net Margin % is 1.53. Ebos Group's value of 1.84% is 20.3% above this industry median. Based on the distribution chart, Ebos Group ranks #56 out of 119 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Ebos Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Net Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #56 out of 119 companies for Net Margin %. This puts Ebos Group in the upper half of its industry. The industry median Net Margin % is 1.53. Ebos Group's value of 1.84% is 20.3% above this benchmark. Historically, Ebos Group's own Net Margin % has ranged from 1.74 to 2.07 over the past decade. While the company's 10-year median is 1.93 vs. the industry median of 1.53, Ebos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Distribution company?
The median Net Margin % among Medical Distribution companies is 1.53, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current Net Margin % of 1.84% is 20.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median Net Margin % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Net Margin % is 1.84%, which is near median its own 10-year median of 1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.49, compared to a current price of A$16.76 — trading 46.8% below its estimated fair value. The current Net Margin % is 1.84%, which is near median its 10-year median of 1.93 and 20.3% above the Medical Distribution industry median of 1.53. Ebos Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current Net Margin % is 1.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$16.76 is trading 46.8% below its estimated GF Value™ of A$31.49.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
Net Margin %: 1.84% (near median its 10-year median of 1.93)
GF Value™: A$31.49 vs. price of A$16.76 (46.8% below fair value)
Industry Position: 20.3% above the Medical Distribution median (#56 of 119)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score
Get the complete analysis for ASX:EBO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
